跳至主要内容
临床试验/JPRN-jRCT2080224070
JPRN-jRCT2080224070已完成3 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Ulcerative Colitis [M14-675]

AbbVie GK0 个研究点目标入组 522 人开始时间: 2018年9月28日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
AbbVie GK
入组人数
522

研究概览

简要总结

Achieved statistically significant improvements in efficacy primary endpoint in UPA vs PBO. The treatment was well tolerated; AEs were consistent with the known safety profile of UPA with no new safety signals identified.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 16age old 至 <= 75age old(—)
性别
All

入选标准

  • Diagnosis of Ulcerative Colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.
  • - Active UC with an Adapted Mayo score of 5 to 9 points and endoscopic subscore of 2 to 3.
  • - Demonstrated an inadequate response, loss of response, or intolerance to at lease one of the following treatments including, oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies.
  • - Female Participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit.
  • - If female, participant must meet the contraception recommendation criteria.

排除标准

  • 未提供

研究者

发起方
AbbVie GK

相似试验